Skip to main content

leadership_change

Kalohexis Names TCR2 Ex-CEO Garry Menzel to Board

Kalohexis Names TCR2 Ex-CEO Garry Menzel to Board

Northbrook, Illinois – September 05, 2026 -- Kalohexis, Inc. has appointed Garry Menzel, Ph.D., to its Board of Directors, adding an executive who raised more than $500 million while leading oncology company TCR2 Therapeutics before its 2023 merger with Adaptimmune.

Menzel brings deal experience spanning $100 billion in biotech transactions

Menzel currently serves as an Operating Partner at Global Healthcare Opportunities (GHO) Capital, a European healthcare-focused private equity firm. He previously worked as an investment banker at Goldman Sachs and Credit Suisse, where he led global biotechnology franchises and worked on transactions totaling more than $100 billion, including IPOs and M&A deals.

NYU Langone Names Frankle Chair of Psychiatry Department

NYU Langone Names Frankle Chair of Psychiatry Department

NEW YORK – September 04, 2026 -- NYU Langone Health has appointed William Gordon Frankle, MD, MBA, as chair of the Department of Psychiatry at NYU Grossman School of Medicine, effective September.

Frankle succeeds Marmar after 17-year tenure

Dr. Frankle takes over from Charles R. Marmar, MD, who completed 17 years as chair and will continue as director of the Center for Precision Psychiatry within NYU Grossman School of Medicine's faculty. Frankle previously served as vice chair of the department and chief of psychiatry service at NYU Langone Hospital—Brooklyn, and holds the title of professor of psychiatry.